Arix Bioscience

Evommune, Inc. is a biotechnology company based in Los Altos, California, that develops and manufactures tissue-based medicines for inflammatory diseases. Incorporated in 2020, Evommune focuses on creating novel strategies to treat these disorders by addressing both symptoms and the underlying causes, thereby halting disease progression. The company employs a proprietary tissue-based platform that accelerates the discovery of innovative treatments, enhancing the potential for clinical success. With a commitment to improving the quality of life for patients, Evommune's pipeline includes initiatives aimed at tackling a range of prevalent inflammatory illnesses, positioning the company as a leader in advancing therapies in the fields of immunology and dermatology.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Sorriso Pharmaceuticals is a biotechnology company focused on developing disease-modifying antibodies aimed at treating inflammatory diseases such as Crohn's disease and ulcerative colitis. Founded in 2020 and headquartered in San Diego, California, Sorriso's innovative platform generates potent antibodies that can be administered orally, allowing for sustained activity throughout the intestinal system. This oral delivery method offers a significant advantage by alleviating the treatment burden associated with injectable antibody therapeutics, thus improving patient convenience and compliance. Through its research and development efforts, Sorriso Pharmaceuticals aims to provide effective solutions for individuals suffering from these challenging gastrointestinal conditions.

Depixus is a biotechnology company that focuses on advanced genomic analysis through its innovative technology designed for real-time examination of biomolecular interactions. By enabling comprehensive analysis across full genomic regions, the company provides a platform that allows researchers to customize the level of sequencing and epigenetic detail required. This capability facilitates the exploration of new biological pathways, the understanding of disease mechanisms, and the development of precision medicines. Depixus aims to overcome the limitations of current sequencing technologies, which struggle to capture dynamic molecular interactions with single-molecule precision, thus enhancing the ability to unlock valuable insights in genomic research.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases by targeting gasdermin proteins. The company specializes in gasdermin biology and innate immunity to create innovative medicines. Its lead compounds specifically target and inhibit Gasdermin D, a key protein involved in pyroptosis and NETosis pathways, which play significant roles in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). Established in 2018 and previously known as Project Pyro, Quench Bio aims to provide effective treatments that alleviate the symptoms of severe inflammatory conditions.

Stipe Therapeutics is a biopharmaceutical company based in Aarhus C, Denmark, founded in 2018. The company specializes in developing peptide therapeutics aimed at eliminating tumors and combating cancer by harnessing the innate immune system. Stipe Therapeutics focuses on creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway, which plays a crucial role in innate immunity and the regulation of tumorigenesis and autoimmune disorders. Through the identification and validation of compounds that sensitize the STING pathway, Stipe Therapeutics aims to modulate the tumor microenvironment, thereby enhancing the body's anti-tumoral responses and improving treatment outcomes for cancer patients.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various hematological cancers and solid tumors. Established in 2017, the company specializes in therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1), a protein present on many cancerous cells but absent in normal tissues, making it a promising target for cancer treatment. VelosBio's lead product, VLS-101, is an ROR1-directed ADC designed for patients with both hematologic and solid tumor malignancies. The company's approach aims to provide novel targeted therapies that can be utilized as monotherapy or in combination with other treatments across a wide array of cancer types.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases by targeting gasdermin proteins. The company specializes in gasdermin biology and innate immunity to create innovative medicines. Its lead compounds specifically target and inhibit Gasdermin D, a key protein involved in pyroptosis and NETosis pathways, which play significant roles in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). Established in 2018 and previously known as Project Pyro, Quench Bio aims to provide effective treatments that alleviate the symptoms of severe inflammatory conditions.

Aura Biosciences, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies aimed at targeting and destroying cancer cells through viral nanoparticle conjugates. The company's lead product, AU-011, utilizes viral nanoparticles modeled on the human papillomavirus, conjugated with infrared-activated small molecules, specifically for the treatment of ocular melanoma, a primary cancer of the eye. Aura Biosciences aims to address the challenges of treating small ocular melanomas early in the disease progression to prevent metastasis, particularly to the liver, which is often fatal. In addition to ocular oncology, the company is exploring applications of its platform in other indications, including bladder cancer. Founded in 2007, Aura Biosciences is committed to advancing precision immunotherapies designed to preserve organ function while effectively managing a range of solid tumors.

Atox Bio Inc. is a biotechnology company based in Ness Ziona, Israel, with an additional office in North Carolina. Founded in 2003, the company specializes in developing immunomodulators aimed at treating critically ill patients facing severe acute inflammation due to infections. Atox Bio focuses on novel modulators of the immune response, targeting both adaptive and innate pathways that play crucial roles in managing infectious and inflammatory diseases, as well as ischemia/reperfusion injuries. The company's products are designed to improve outcomes for patients suffering from rare, life-threatening infections, demonstrating significant improvements in various clinical endpoints. By enhancing the host's ability to combat infections and minimizing tissue damage during acute inflammatory events, Atox Bio aims to address serious unmet medical needs in critical care settings.

Autolus Therapeutics is a biopharmaceutical company based in London, England, focused on developing next-generation programmed T cell therapies for cancer treatment. Founded in 2014 by Tim Funnell and Martin Pule, the company has established a clinical-stage pipeline that includes several innovative therapies, such as Obe-cel (obecabtagene autoleucel) and others designated as AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Through its research and development efforts, Autolus aims to advance the field of cancer immunotherapy and improve outcomes for patients battling various types of cancer.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

PreciThera, Inc. is a biotechnology company based in Montreal, Canada, founded in 2016. It specializes in developing biological therapeutics for rare bone diseases, particularly targeting heterogeneous genetic disorders that manifest as bone dysfunction. By leveraging computational technology and a comprehensive understanding of disease pathology, PreciThera aims to create precision medicines that address both skeletal and extraskeletal symptoms associated with these conditions. Its targeted therapeutic strategies seek to enhance treatment options for patients, focusing on traditional protein replacement therapies to improve overall health outcomes.

LogicBio Therapeutics, Inc. is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly for pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology platform, LogicBio aims to integrate corrective genes into patients' genomes to achieve therapeutic effects. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a serious condition that manifests at birth. Additionally, LogicBio is advancing other product candidates, including LB-101 and LB-301, the latter developed in collaboration with Takeda Pharmaceutical Company to address Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors, enhancing the potential of its gene therapy approaches. Founded in 2014, LogicBio is headquartered in Lexington, Massachusetts.

Mitoconix Bio Ltd is a biotechnology company established in 2016 and headquartered in Jerusalem, Israel, focused on developing innovative therapies aimed at enhancing mitochondrial health to treat neurodegenerative diseases. The company employs a disease-modifying approach that targets the functions of mitochondria, which are essential for generating ATP, regulating calcium, and maintaining cellular balance. Mitochondria play a crucial role in neuron function, undergoing constant changes in structure through processes known as fission and fusion. Disruptions in these processes can lead to reduced energy production and increased oxidative stress, contributing to cellular dysfunction and death. Mitoconix's lead drug is a first-in-class inhibitor designed to counteract pathological mitochondrial fragmentation and has shown promising efficacy in preclinical models of Huntington's disease and Parkinson's disease, as well as beneficial effects in patient-derived cells associated with these conditions and Alzheimer's disease.

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company based in South San Francisco, California, focused on developing a novel class of T cell engagers to harness the body's immune system for treating cancer and other diseases. The company utilizes its proprietary TriTAC (Tri-specific T cell Activating Construct) platform to create engineered proteins that direct T cells to target and kill cells expressing specific antigens. Harpoon's lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, the company is advancing other candidates, including HPN536, which is in Phase I/IIa trials for ovarian cancer and MSLN-expressing tumors, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Harpoon Therapeutics was founded in 2015 and is committed to addressing unmet medical needs in oncology through innovative therapies.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company based in Dublin, Ireland, focused on developing innovative anti-infectives to address the pressing issue of multi-drug resistant pathogens. Founded in 2015, the company is advancing sulopenem, a novel penem anti-infective compound that is currently undergoing Phase III clinical trials. Sulopenem is designed for both oral and intravenous use and aims to treat various serious infections, including uncomplicated and complicated urinary tract infections as well as complicated intra-abdominal infections. The company’s mission is to significantly improve the lives of patients affected by serious and life-threatening diseases by providing effective solutions to antibiotic resistance.

Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2016, the company is dedicated to creating first-in-class therapies that selectively kill cancer cells by exploiting their reliance on DDR mechanisms. Artios’ product pipeline includes a range of promising candidates, such as a therapy that targets DNA polymerase theta, a protein involved in DNA repair processes, and another program focusing on a novel DDR target. The company collaborates with prominent research organizations, including Cancer Research Technology, to enhance its development efforts and leverage expertise in DNA repair. Artios is led by a skilled team with extensive experience in drug discovery, positioning it to advance its next-generation DDR programs and contribute significantly to the field of cancer treatment.

Autolus Therapeutics is a biopharmaceutical company based in London, England, focused on developing next-generation programmed T cell therapies for cancer treatment. Founded in 2014 by Tim Funnell and Martin Pule, the company has established a clinical-stage pipeline that includes several innovative therapies, such as Obe-cel (obecabtagene autoleucel) and others designated as AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8. Through its research and development efforts, Autolus aims to advance the field of cancer immunotherapy and improve outcomes for patients battling various types of cancer.